Health
LoDoCo2: Added Steam for Colchicine as Secondary Prevention – Medscape
The benefits emerged early and continued to accrue through the trial, with no suggestion of attenuation during up to 5 years of treatment.
The anti-inflammatory drug colchicine picked up new support as secondary prevention in chronic coronary disease, cutting the risk of cardiovascular events by one third when added to standard prevention therapies in the double-blind LoDoCo2 study.
Across a median follow up of 29 months in more than 5000 patients, almost 1 in 10 patients assigned to placebo experienced the primary endpoint of cardiovascular (CV) death, myocardial infarction (MI), ischemic stroke, or ischemia-driven coronary revas…
-
General24 hours agoDairy farmers devastated by floods across parts of New South Wales
-
Noosa News21 hours agoBrisbane’s Triffid forces redesign of $1.5 billion tower project
-
Noosa News24 hours agoMan dies in Gold Coast after rolling trailer pins him to lamp-post
-
General20 hours agoSussan Ley’s office says Bridget McKenzie made false claims about cabinet solidarity